![]() ![]() He received his doctorate in Cellular and Molecular Biology from West Virginia University, and is a Fellow of the Academy of Toxicological Sciences.ĭr. He received his Bachelor of Arts degree in Biology/Chemistry and his Masters of Arts in Biomedical Sciences from Western Michigan University. Ulrich holds several patents and has authored more than 125 publications. Ulrich was Senior Scientific Director with Merck Research Laboratories/Rosetta Inpharmatics, Director of Regulatory Toxicology, Safety Pharmacology, Genetic Toxicology, Cellular and Molecular Toxicology, Microscopy and Microanalysis at Abbott Laboratories, and a Senior Scientist with The Upjohn Company and Pharmacia & Upjohn Inc. ![]() ![]() Prior to Acerta, he was Founder and Chief Development Officer at Calistoga Pharmaceuticals Inc., which was acquired by Gilead Sciences in 2011. ![]() Most recently he served as Chief Scientific Officer and a member of the Board of Directors at Acerta Pharma BV until the majority acquisition by AstraZeneca in 2016. He is currently a Senior Advisor to Frazier Healthcare Partners and a Scientific Advisor to BioGeneration Ventures, and is a member of several small pharma Board of Directors and Scientific Advisory Boards. Ulrich is an entrepreneur and biotech executive with more than 35 years of operational and administrative experience in the pharmaceutical industry. Dukes holds Master of Jurisprudence and Doctorate of Philosophy degrees from the University of Oxford, a Master of Science degree in Cardiovascular Studies from the University of Leeds, and a Bachelor of Science degree in Pharmacology from the University of Bath.ĭr. Dukes was Vice President of Scientific and Technology Licensing at GlaxoSmithKline, and prior to that, from 1990 to 1999, he held various positions at Glaxo Wellcome, including Head of Exploratory Development for Metabolic and Urogenital Diseases and Head of Ion Channel Drug Discovery Group. Dukes was the President and Chief Executive Officer, and a member of the board of directors, of Essentialis Therapeutics, a clinical stage biotechnology company focused on the development of breakthrough medicines for the treatment of rare metabolic diseases. Dukes was Vice-President of External Research & Development at Amgen, from August 2010 to August 2013. Dukes previously served as Senior Vice-President and Head of Business Development and Licensing for Merck Research Laboratories through May 2016. He also serves on the Boards of KaNDy Therapeutics (previously as Chairman), NeRRe Therapeutics, ENYO, Kyn Therapeutics and ReViral.ĭr. Iain Dukes is currently Chairman of Iovance Biotherapeutics (NASQ:IOVA) and CEO of Theseus Pharmaceuticals and Viriom. He is listed as an inventor on many scientific patents and is published in numerous medical journals, including the NEJM, the Lancet and the Journal of Clinical Oncology. Rothbaum graduated Phi Beta Kappa from Binghamton University in 1990 with a dual major in political science and psychology and received his MA in international economics from The George Washington University. Rothbaum is a board member and its largest shareholder. Rothbaum has taken a leadership role in transforming Iovance, restructuring and reorganizing its Board of Directors, senior management and overall clinical operations and strategy. More recently, in 2019, he co-founded Telios Pharma after licensing a novel targeted therapy from Merck KGaA to treat selected blood cancers and ophthalmology diseases. Rothbaum also co-founded Kartos Therapeutics following the in-license of an investigational MDM2 inhibitor from Amgen. Acerta’s lead drug, Calquence (acalabrutinib) was approved by the FDA for mantle cell lymphoma in 2017 and CLL in 2020. Rothbaum co-founded and was the Executive Chairman of Acerta Pharma, a private life sciences company he later sold to AstraZeneca. Rothbaum founded Quogue Capital, through which he has started and/or invested in numerous private and public life sciences companies. Following The Carson Group’s sale to Thomson Reuters in 2001, Mr. Rothbaum began his career at The Carson Group, a strategic consulting firm, where he managed its life sciences practice and boutique investment bank Evolution Capital. Wayne Rothbaum is president of Quogue Capital, a single-family office private equity fund focused on investing and supporting small to midcap life sciences companies. ![]()
0 Comments
Leave a Reply. |